Vet Comp Oncol. 2020 Nov 2. doi: 10.1111/vco.12661. Online ahead of print.
In humans B-symptoms refer to systemic symptoms of lymphoma such as fever, weight loss, and night sweats and influence the prognosis of patients. In canine lymphoma, substage B is used to describe any clinical sign observed. Aim of the retrospective study was to compare the prognostic value of substage B with B-symptoms to predict treatment response and survival in canine nodal diffuse large B-cell lymphoma. Affected dogs treated with CHOP chemotherapy between 2008-2019 were included. B-symptoms
were defined by weight loss greater than 10% of normal weight, fever and the occurrence of unexplained resting tachypnoea substituted human night sweats. Substage B was defined as any symptoms but lymphadenopathy. Fifty-five cases were included. B-symptoms were present in 20/55 (36%) and substage B in 40/55 (74%) patients. No significant associations between B-symptoms or substage B and weight, sex, breed, WHO stage and lymphoma grade were found. Treatment response was negatively associated with both substage B (P=0.02) and B-symptoms (P=0.001). B-symptoms significantly decreased progression free survival (PFS) (95 vs. 330 days, P=0.001) and lymphoma specific survival (LSS) (160 vs. 462 days, P=0.001). Data showed that B-symptoms might be a more reliable prognostic indicator than substage B in canine nodal diffuse large B-cell lymphoma. Prospective studies assessing B-symptoms in a larger cohort of patients and in other common lymphoma types are warranted. The abstract was presented at the 4th meeting of the European Canine Lymphoma Network Group in Lugano, June 22, 2019 and published in the proceeding of the meeting on the page 26. This article is protected by copyright. All rights reserved.